Drugs / INCB161734
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07018635 | Jul → Sep 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06179160 | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07522073 | Apr 2026 → Sep 2028 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Incyte Corporation | Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 incyte.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB161734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07018635 ↗ |
| Route | Oral | “Oral; Tablet” NCT07018635 ↗ |